Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis

[1]  C. Polman,et al.  Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of Interferon beta-1b in patients with Secondary Progressive Multiple Sclerosis , 2005, Journal of Neurology.

[2]  X. Montalban.  Overview of European pilot study of interferon b-1b in primary progressive multiple sclerosis , 2004, Multiple sclerosis.

[3]  W. Brück,et al.  The role of cytokines and adhesion molecules in axon degeneration after peripheral nerve axotomy: a study in different knockout mice , 2003, Brain Research.

[4]  Carlos Nos,et al.  Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials , 2002, Annals of neurology.

[5]  M. Kaps,et al.  Induction of sTNF‐R1 and sTNF‐R2 by interferon beta‐1b in correlation with clinical and MRI activity , 2001, Acta neurologica Scandinavica.

[6]  P. Gallo,et al.  Interleukin-1 receptor antagonist, soluble tumor necrosis factor-a receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-b1a. , 2000 .

[7]  Tarek A. Yousry,et al.  Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility , 1999, Neuroradiology.

[8]  X. Montalban,et al.  Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. , 1999, Brain : a journal of neurology.

[9]  Stephen M. Rao,et al.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.

[10]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[11]  J. Dayer,et al.  Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. , 1997, European cytokine network.

[12]  F. Barkhof,et al.  Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 , 1996, Neurology.

[13]  F. Nicoletti,et al.  Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. , 1996, Cytokine.

[14]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[15]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[16]  A. Broocks,et al.  Tumor necrosis factor‐α messenger RNA expression in patients with relapsing‐remitting multiple sclerosis is associated with disease activity , 1995, Annals of neurology.

[17]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[18]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[19]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[20]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[21]  C. Dinarello,et al.  Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. , 1991, The Journal of biological chemistry.

[22]  D. Dripps,et al.  Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. , 1991, The Journal of biological chemistry.

[23]  C. Nathan,et al.  Shedding of tumor necrosis factor receptors by activated human neutrophils , 1990, The Journal of experimental medicine.

[24]  D. Wallach,et al.  A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. , 1989, The Journal of biological chemistry.

[25]  J. Dayer,et al.  Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. , 1989, The Journal of biological chemistry.

[26]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[27]  M. Filippi,et al.  Primary Progressive Multiple Sclerosis , 2002, Topics in Neuroscience.

[28]  G. Wong,et al.  TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination , 1998, Nature Medicine.